News and Trends 2 Dec 2022
Khondrion’s sonlicromanol produces encouraging results for next stage of study
Biopharma company, Khondrion, has marked announced improvements from patients with MELAS spectrum disorders taking its lead asset, sonlicromanol. Updates were provided by the company from a 28-day double-blind, randomized placebo-controlled,…
